Dexcom (DXCM) is a publicly traded Healthcare sector company. As of May 20, 2026, DXCM trades at $71.03 with a market cap of $25.12B and a P/E ratio of 33.13. DXCM moved +6.60% today. Year to date, DXCM is +5.60%; over the trailing twelve months it is -18.20%. Its 52-week range spans $54.11 to $93.25. Analyst consensus is strong buy with an average price target of $80.10. Rallies surfaces DXCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Dexcom Upgraded to Buy on Forecasted Gross Margin Increase through 2026: Benchmark upgraded Dexcom to Buy, highlighting potential margin expansion as G7 shipments scale and factory cost efficiencies improve. The firm noted operational leverage could boost gross margins by several percentage points through 2026.
| Metric | Value |
|---|---|
| Price | $71.03 |
| Market Cap | $25.12B |
| P/E Ratio | 33.13 |
| EPS | $2.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.25 |
| 52-Week Low | $54.11 |
| Volume | 9.83M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.66B |
| Net Income | $836.30M |
| Gross Margin | 60.10% |
21 analysts cover DXCM: 0 strong buy, 19 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.10.